Articles by Jamie Koprivnikar, MD
MDS experts tell of the clinical factors they consider when selecting from the available agent options.
An MDS expert panel discusses findings from the trial's comparison of luspatercept with ESAs in this setting.
The panel discusses forward-looking thoughts for the treatment of low-risk MDS.
The panel talks about the use of transplant for patients with low-risk myelodysplastic syndromes.
The panel discusses other treatments undergoing research for MDS, including imetelstat and KER-050.
The panel shared their thoughts on real-world data of luspatercept presented at ASH 2023.
The panel addresses continued MDS research needs.
The panel discusses appropriate treatment selection based on patient mutation status and comorbidities.
The panel shares their thoughts on the full analysis of the COMMANDS study.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.